Management of diabetic nephropathy: Recent progress and future perspective

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 9, Issue 4, 2015, Pages 343-358

  Ahmad, Jamal ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Albuminuria; Diabetic nephropathy; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

COMPLICATION; DIABETIC NEPHROPATHIES; DISEASE COURSE; DISEASE MANAGEMENT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; PROGNOSIS;

EID: 84926196565     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2015.02.008     Document Type: Review

References (150)

1. G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose), and et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systemic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 2011 31 40
2. R.C. Alkins, and P. Zimmet Diabetic kidney disease: act now or pay later Kidney Int 77 2010 375 377
3. M.E. Cooper Diabetes: treating diabetic nephropathy-still an unresolved issue Nat Rev Endocrinol 8 2012 515 516
4. M. Schwartz, E. Lewis, T. Leonard-Martin, J. Lewis, and S.G. Batlle Dat Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy Nephrop Dial Transplant 13 1998 2547 2552
5. R. Osterby, M. Gall, A. Schmitz, F.S. Nielsen, G. Nyberg, and H. Parving Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients Diabetology 36 1993 1064 1070
6. National Kidney Foundation KDOQ1 clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease Am J Kidney Dis 49 Suppl. 2 2007 S1 S180
7. C.E. Mogensen, and C.K. Christensen Predicting diabetic nephropathy in insulin-dependent patients N Engl J Med 311 1984 89 93
8. H.H. Parving, B. Oxenboll, P.A. Svendsen, J.S. Christiansen, and A.R. Andersen Early detection of patients at risk of developing diabetic nephropathy: a longitudinal study of urinary albumin excretion Acta Endocrinol (Copenh) 100 1982 550 552
9. G.C. Viberti, R.D. Hill, R.J. Jarrett, A. Argyropoulos, U. Mahmud, and H. Keen Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus Lancet 1 1982 1430 1432
10. C.E. Mogensen Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes N Engl J Med 310 1984 356 360
11. M. Chaturvedi, S. Bandinellis, R. Mangili, G. Penno, R.E. Rottiers, and J.H. Fulleer Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold Kidney Int 60 2001 219 227
12. P. Hovind, L. Tarnow, P. Rossing, B.R. Jensen, M. Graae, I. Torp, and et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study BMJ 328 2004 1105 1108
13. A.I. Adler, R.J. Stevens, S.E. Manley, R.W. Bilous, C.A. Cull, and R.R. Holman Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int 63 2003 225 232
14. C.T. Valmadrid, R. Klein, S.E. Moss, and B.E. Klein The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus Arch Intern Med 160 2000 1093 1100
15. J. Karalliedde, and G. Viberti Microalbuminuria and cardiovascular risk Am J Hypertens 17 2004 986 993
16. C.E. Mogensen Glomerular hyperfiltration in human diabetes Diabetes Care 17 1994 770 775
17. C. Mogensen C. Mogensen, In the kidney and hypertension in diabetes mellitus 2006 Taylor and Francis London 883 938
18. A.D. Rule, T.S. Larson, E.J. Bergstralh, J.M. Slezak, S.J. Jacobsen, and F.G. Cosio Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease Ann Intern Med 141 2004 929 937
19. P. Cotroneo, A. Manto, L. Todaro, A. Manto Jr., D. Pitocco, C. Saponara, and et al. Hyperfiltration in patients with type I diabetes mellitus: a prevalence study Clin Nephrol 50 1998 214 217
20. C.E. Mogensen Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas Diabetologia 42 1999 263 285
21. E. Premaratne, R.J. Macisaac, C. Tsalamandris, S. Panagiotopoulos, T. Smith, and G. Jerums Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate Diabetologia 48 2005 2486 2493
22. G. Magee, R. Bilous, C. Cardwell, S. Hunter, F. Kee, and D. Fogarty Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis Diabetologia 52 2009 691 697
23. L.H. Ficociello, B.A. Perkins, B. Roshan, J.M. Weinberg, A. Aschengrau, J.H. Warram, and et al. Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes Diabetes Care 32 2009 889 893
24. D. Cherney, J. Scholey, and J. Miller Insights into the regulation of renal hemodynamic function in diabetic mellitus Curr Diabetes Rev 4 2008 280 290
25. E. Lurbe, J. Redon, and A. Kesani Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes N Engl J Med 347 2002 797 805
26. J.A. Fagerudd, L. Tarnow, P. Jacobsen, S. Stenman, F.S. Nielsen, K.J. Pettersson-Fernholm, and et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients Diabetes 47 1998 439 444
27. J.W. Messent, T.G. Elliott, R.D. Hill, R.J. Jarrett, H. Keen, and G.C. Viberti Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study Kidney Int 41 1992 836 839
28. M.L. Caramori, P. Fioretto, and T. Mauer The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 49 2000 1399 1408
29. D.K. Singh, P. Winocour, and K. Farrington Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy Nat Clin Pract Nephrol 4 2008 216 226
30. S.M. Marshall The podocyte: a major player in the development of diabetic nephropathy? Horm Metab Res 37 Suppl. 1 2005 9 16
31. American Diabetes Association Nephropathy in diabetes (position statement) Diabetes Care 27 Suppl. 1 2004 S79 S83
32. J.M. Stephenson, and J.H. Fuller Microalbuminuria is not rare before 5 years of IDDM EURODIAB IDDM Complications Study Group and the WHO Multinational Study of Vascular Disease in Diabetes Study Group J Diabetes Complic 8 1994 166 173
33. C.J. Schultz, T. Konopelska-Bahu, R.N. Dalton, T.A. Carroll, I. Stratton, E.A. Gale, and et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group Diabetes Care 22 1999 495 502
34. M.L. Caramori, P. Fioretto, and M. Mauer Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients is associated with more diabetic lesions Diabetes 52 2003 1036 1040
35. R.J. MacIsaac, C. Tsalamandris, S. Panagiotopoulos, T.J. Smith, K.J. McNeil, and G. Jerums Nonalbuminuric renal insufficiency in type 2 diabetes Diabetes Care 27 2004 195 200
36. H.J. Kramer, Q.D. Nguyen, G. Curhan, and C.Y. Hsu Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus JAMA 289 2003 3273 3277
37. B.A. Perkins, L.H. Ficociello, B. Roshan, J.H. Warram, and A.S. Krolewski In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria Kidney Int 77 2010 57 64 10.1038/ki.2009.399 [PMID: 19847154 ]
38. P. Fioretto, M.W. Steffes, and M. Mauer Glomerular structure in non-proteinuric IDDM patients with various levels of albuminuria Diabetes 43 1994 1358 1364 10.2337/diab.43.11.1358 [PMID: 7926312]
39. R.D. Perrone, N.E. Madias, and A.S. Levey Serum creatinine as an index of renal function: new insights into old concept Clin Chem 38 1992 1933 1953 [PMID: 1394976]
40. W.M. Michels, D.C. Grootendorst, M. Verduijn, E.G. Elliott, F.W. Dekker, and R.T. Krediet Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size Clin J Am Soc Nephrol 5 2010 1003 1009
41. A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. Castro 3rd, H.I. Feldman, and et al. A new equation to estimate glomerular filtration rate Ann Intern Med 150 2010 604 612
42. A.S. Levey, and L.A. Stevens Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions Am J Kidney Dis 55 2010 622 627
43. L.A. Inker, B.C. Astor, C.H. Fox, T. Isakova, J.P. Lash, C.A. Peralta, and et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD Am J Kidney Dis 63 2014 713 735
44. B.A. Perkins, R.G. Nelson, B.E. Ostrander, K.L. Blouch, A.S. Krolewski, B.D. Myers, and et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study J Am Soc Nephrol 16 2005 1404 1412
45. M. Mussap, M. Dalla Vestra, P. Fioretto, A. Saller, M. Varagnolo, R. Nosadini, and et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients Kidney Int 61 2002 1453 1461
46. C.Y. Hong, and K.S. Chia Markers of diabetic nephropathy J Diabetes Complic 12 1998 43 60
47. G. Currie, G. McKay, and C. Delles Biomarkers in diabetic nephropathy: present and future World J Diabetes 5 2014 763 776
48. S.M. Marshall Clinical features and management of diabetic nephropathy J. Pickup, G. Williams, Text book of diabetes 3rd ed. 2003 Blackwell Science Ltd. Oxford 53.01 53.22
49. P. Ruggenenti, P. Bettinaglio, F. Pinares, and G. Remuzzi Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies Clin J Am Soc Nephrol 3 2008 1511 1525
50. Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow up study Kidney Int 68 2005 250 257
51. D.K. Singh, P. Winocour, and K. Farrington Oxidative stress in early diabetic nephropathy: fueling the fire Nat Rev Endocrinol 7 2011 176 184
52. J.F. Navarro-González, C. Mora-Fernández, M. Muros de Fuentes, and J. García-Pérez Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy Nat Rev Nephrol 7 2011 327 340
53. T. Miyata, and C. Van Yparsele de Strihou Diabetic nephropathy: a disorder of oxygen metabolism? Nat Rev Nephrol 6 2010 83 95
54. A. Tojo, K. Asaba, and M.L. Onozato Suppressing renal NADPH oxidase to treat diabetic nephropathy Expert Opin Ther Targets 11 2014 1011 1018
55. H. Noh, and G.L. King The role of protein kinase C activation in diabetic nephropathy Kidney Int Suppl 72 2007 S49 S53
56. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
57. T. Nishikawa, D. Edelstein, X.L. Du, S. Yamagishi, T. Matsumura, Y. Kaneda, and et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage Nature 404 2011 787 790
58. J. Wada, and H. Makino Inflammation and the pathogenesis of diabetic nephropathy Clin Sci 124 2013 139 152
59. Y. Liu Cellular and molecular mechanisms of renal fibrosis Nat Rev Nephrol 2011 684 696
60. C.E. Hills, and P.E. Squires The role of TGF-β and epithelial-to-mesangial transition in diabetic nephropathy Cytokine Growth Factor Rev 22 2011 131 139
61. G.K. Braga The role of transforming growth factor-beta in diabetic nephropathy Int J Med Genet 2014 1 6
62. K. Yagi, D. Goto, T. Hamamoto, S. Takenoshita, M. Kato, and K. Miyazono Alternatively spliced variant of Smad 2 lacking exon 3: comparison with wild type Smad 2 and Smad-3 J Biol Chem 274 1999 703 709
63. L. Grudi, G. Gruden, and G.C. Viborti Pathogenesis of diabetic nephropathy 3rd ed. J.C. Pickup, G. Williams, Textbook of diabetes 52 2003 Blackwell Science Ltd. Oxford 1 22
64. P.L. Brito, P. Fieoretto, K. Drummond, Y. Kim, M.W. Steffes, J.M. Basgen, and et al. Proximal tubular basement membrane width in insulin-dependent diabetes mellitus Kidney Int 53 1998 754 761
65. E.R. Seaquist, F.C. Goetz, S. Rich, and J. Barbosa Familial clustering of diabetic kidney disease, evidence for genetic susceptibility to diabetic nephropathy N Engl J Med 320 1989 1161 1165
66. R. Trevisan, J.D. Walker, and G.C. Viberti Diabetic nephropathy R. Jamison, R. Wilkinson, Nephrology 2nd ed. 1997 Chapman and Hall London 551 574
67. B.I. Freedman, M. Bostrom, P. Daeihagh, and D.W. Bowden Genetic factors in diabetic nephropathy Clin J Am Soc Nephrol 2 2007 1306 1316
68. J.R. Schelling, H.E. Abboud, S.B. Nicholas, M.V. Pahl, J.R. Sedor, S.G. Adler, and et al. Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: the Family Investigation of Nephropathy and Diabetes (FIND) Diabetes 57 2007 235 243
69. P.W. Mueller, J.J. Rogus, P.A. Cleary, Y. Zhao, A.M. Smiles, M.W. Steffes, and et al. Genetics of Kidneys in Diabetes (GoKinD) study: a genetic collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes J Am Soc Nephrol 17 2006 1782 1790
70. R. Trevisan, and G. Viberti Sodium-hydrogen antiporter: its possible role in the genesis of diabetic nephropathy Nephrol Dial Transplant 12 1997 643 645
71. L. Gnudi, G. Gruden, and G.C. Viberti Pathogenesis of diabetic nephropathy 3rd ed. J.C. Pickup, G. Williams, Textbook of diabetes vol. 52 2003 Blackwell Science Ltd. Oxford 1 22
72. T. Zelmanovitz, J. Oliveira, and M.J. de Azevedo Screening for diabetic nephropathy: is measurement of urinary albumin-to-creatinine ratio worthwhile? Diabetes Care 22 1999 1599 1600
73. National Institute for Clinical Excellence (NICE) Early identification and management of chronic kidney disease in adults in primary and secondary care. Clinical guidelines CG73 2008 NICE London Available from: http://guidelines.nice.org.UK/CG73 (accessed June 2010)
74. Diabetes Control and Complication Trial (DCCT) Research Group Effect of intensive therapy on the development of and progression of diabetic nephropathy in the Diabetes Control and Complication Trial Kidney Int 47 1995 1703 1720
75. R. Bilous Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 25 Suppl. 2 2008 25 29
76. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Sustained effect of intensive treatment of type 1 diabetes mellitus on the development of and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study JAMA 290 2003 2159 2167
77. The DCCT/EDIC Research Group Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes N Engl J Med 365 2011 2366 2376
78. The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
79. N. Ismail, B. Becker, P. Strzelezyk, and E. Ritz Renal disease and hypertension in non-insulin dependent diabetes mellitus Kidney Int 55 1999 1 28
80. C. Keller, K. Bergis, D. Filser, and E. Ritz Renal findings in patients with short term type-2 diabetes J Am Soc Nephrol 7 1996 2627 2635
81. K. Nørgaard, B. Feldt-Rasmussen, K. Borch-Johnsen, H. Saelan, and T. Deckert Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus Diabetologia 33 1990 407 419
82. C.E. Mogensen Long term antihypertensive treatment inhibiting progression of diabetic nephropathy Br Med J 285 1982 685 688
83. H. Parving, A. Anderson, U. Smioth, and P. Svendsen early aggression antihypertensive treatment reduces rate of decline of kidney function in diabetic nephropathy Lancet 321 1983 1175 1179
84. H. Parving, A. Anderson, U. Smith, E. Hommet, E. Mathiesen, and P. Suendsen Effect of antihypertensive treatment on kidney function in diabetic nephropathy Br Med J 294 1987 1443 1447
85. R.R. Holman, S.K. Paul, M.A. Bethel, H.A. Neil, and D.R. Mathews Long term follow-up after tight control of blood pressure in type 2 diabetes N Engl J Med 359 2008 1565 1576
86. P. Ruggenenti, A. Fassi, A.P. Ileva, S. Bruno, J.P. Iliev, U. Brusegan, and et al. Preventing microalbuminuria in type 2 diabetes N Engl J Med 351 2004 1941 1951
87. ADVANCE Collaborative Group Effect of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcome in patients with type 2 diabetes mellitus (ADVANCE) trial: a randomized controlled trial Lancet 370 2007 829 840
88. R. Bilous, N. Chaturbedi, A.K. Sjolie, J. Fuller, R. Klein, T. Orchard, and et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials Ann Intern Med 151 2009 11 20
89. The DCCT/EDIC Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.
90. J.J. Bending, G.C. Viberti, R.W. Bilous, and H. Keen Eight-month correction of hyperglycemia in insulin-dependent diabetes mellitus is associated with a significant and sustained reduction of urinary albumin excretion rates in patients with microalbuminuria Diabetes 34 August (Suppl. 3) 1985 69 73
91. P.H. Wang, J. Lau, and T.C. Chalmers Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes Lancet 341 8856 1993 1306 1309
92. Microalbuminuria Collaborative Study Group, United Kingdom Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria BMJ 311 October (7011) 1995 973 977
93. D.J. Newman, M.B. Mattock, A.B. Dawnay, S. Kerry, A. McGuire, M. Yaqoob, and et al. Systematic review on urine albumin testing for early detection of diabetic complications Health Technol Assess 9 August (30) 2005 iii-vi, xiii-163
94. J. Ahmad, S. Shafiqui, S.M.A. Abidi, and I. Parvez Effect of 5-year enalaprin therapy on progression of microalbuminuria and glomerular structure changes in type 1 diabetic subject Diab Res Clin Pract 60 2003 134 138
95. ACE Inhibitors in Diabetic Nephropathy Trialist Group Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data Ann Intern Med 134 March (5) 2001 370 379
96. J. Karalliedde, and G. Viberti Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes J Hum Hypertens 20 April (4) 2006 239 253
97. J. Ahmad, M.A. Siddiqui, and H. Ahmad Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria Diabetes Care 20 October (10) 1997 1576 1581
98. T. Sano, N. Hotta, T. Kawamura, H. Matsumae, S. Chaya, H. Sasaki, and et al. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study Diabet Med 13 February (2) 1996 120 124
99. P. Gaede, P. Vedel, H.H. Parving, and O. Pedersen Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study Lancet 353 February (9153) 1999 617 622
100. P. Gaede, L. Tarnow, P. Vedel, H.H. Parving, and O. Pedersen Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria Nephrol Dial Transplant 19 November (11) 2004 2784 2788
101. P. Gaede, H. Lund-Andersen, H.H. Parving, and O. Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 February (6) 2008 580 591
102. J.J. Bending, G.C. Viberti, P.J. Watkins, and H. Keen Intermittent clinical proteinuria and renal function in diabetes: evolution and the effect of glycaemic control Br Med J (Clin Res Ed) 292 January (6513) 1986 83 86
103. E.J. Lewis, L.G. Hunsicker, R.P. Bain, and R.D. Rohde The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 November (20) 1993 1456 1462
104. H.H. Parving, F. Persson, J.B. Lewis, E.J. Lewis, N.K. Hollenberg, and AVOID Study Investigators Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 June (23) 2008 2433 2446
105. J.F. Mann, R.E. Schmieder, M. McQueen, L. Dyal, H. Schumacher, J. Pogue, and et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 August (9638) 2008 547 553
106. National Institute for Clinical Excellence (NICE) Type 2 diabetes: the management of type 2 diabetes 2008 Clinical Guidelines (G66). Available from: http://guidance.nice.org.uk/G66 (accessed June 2010)
107. American Diabetes Association Standards of medical care in diabetes - 2007 Diabetes Care 30 January (Suppl. 1) 2007 S4 S41
108. G.M. Keating, and K.F. Croom Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus Drugs 67 2007 121 153
109. L.F. Fried, T.J. Orchard, and B.L. Kasiske Effect of lipid reduction on the progression of renal disease: a meta-analysis Kidney Int 59 2001 260 269
110. The Heart Protection Study MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
111. J. Sorof, C. Berne, A. Siewert-Delle, L. Jørgensen, P. Sager, and URANUS Study Investigators Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients Diabetes Res Clin Pract 72 2006 81 87
112. T. Nakamura, C. Ushiyama, K. Hirokawa, S. Osada, N. Shimada, and H. Koide Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia Am J Nephrol 21 2001 449 454
113. J.C. Ansquer, C. Foucher, S. Rattier, M.R. Taskinen, G. Steiner, and DAIS Investigators Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis 45 2005 485 493
114. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, and et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
115. R.P. Radermecker, and A.J. Scheen Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes Rev Med Liege 60 2005 957 961
116. K. Endo, Y. Miyashita, H. Sasaki, M. Ohira, A. Saiki, N. Koide, and et al. Probucol delays progression of diabetic nephropathy Diabetes Res Clin Pract 71 2006 156 163
117. P.H. Gaede, P.V. Jepsen, J.N. Larsen, G.V. Jensen, H.H. Parving, and O.B. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
118. C. Cárdenas, E. Bordiu, J. Bagazgoitia, A.L. Calle-Pascual, and Diabetes Nutrition Study Group, Spanish Diabetes Association Polyunsaturated fatty acid consumption may play a role in the onset and regression of microalbuminuria in well-controlled type 1 and type 2 diabetic people: a 7-year, prospective, population-based, observational multicenter study Diabetes Care 27 2004 1454 1457
119. L. Robertson, N. Waugh, and A. Robertson Protein restriction for diabetic renal disease Cochrane Database Syst Rev 2007 4
120. B. Dussol, C. Iovanna, D. Raccah, P. Darmon, S. Morange, P. Vague, and et al. A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy J Ren Nutr 15 2005 398 406
121. C.M. Forsblom, T. Sane, P.H. Groop, K.J. Tötterman, M. Kallio, C. Saloranta, and et al. Risk factors for mortality in type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4 Diabetologia 41 1998 1253 1262
122. J. Cederholm, B. Eliasson, P.M. Nilsson, L. Weiss, S. Gudbjörnsdottir, and Steering Committee of the Swedish National Diabetes Register Microalbuminuria and risk factors in type 1 and type 2 diabetic patients Diabetes Res Clin Pract 67 2005 258 266
123. G. Gambaro, G. Bax, M. Fusaro, M. Normanno, S.M. Manani, M. Zanella, and et al. Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus Diabetes Nutr Metab Clin Exp 14 2001 337 342
124. F. Zheng, Y.J. Zeng, A.R. Plati, S.J. Elliot, M. Berho, M. Potier, and et al. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice Kidney Int 70 2006 507 514
125. M. Williams, W. Bolton, R. Khalifah, T. Degenhardt, R. Schotzinger, and J. McGill Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy Am J Nephrol 27 2007 605 614
126. E.J. Lewis, T. Greene, S. Spitalewiz, S. Blumenthal, T. Berl, Collaborative Study Group, and et al. Pyridorin in type 2 diabetic nephropathy J Am Soc Nephrol 23 2012 131 136
127. K.R. Tuttle, G.L. Bakris, R.D. Toto, J.B. McGill, K. Hu, and P.W. Anderson The effect of ruboxistaurin on nephropathy in type 2 diabetes Diabetes Care 28 2005 2686 2690
128. K.R. Tuttle, J.B. McGill, D.J. Haney, T.E. Lin, and P.W. Anderson Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease Clin J Am Soc Nephrol 2 2007 631 636
129. K. Sharma, J.H. Ix, A.V. Mathew, M. Cho, A. Pflueger, S.R. Dunn, and et al. Pirfenidone for diabetic nephropathy J Am Soc Nephrol 22 2011 1144 1151
130. G. Gambaro, I. Kinalska, A. Oksa, P. Pont'uch, M. Hertlová, J. Olsovsky, and et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The DINAS Randomized Trial J Am Soc Nephrol 13 2002 1615 1625
131. D.K. Packham, R. Wolfe, A.T. Reutens, T. Berl, H.L. Heerspink, R. Rohde, and et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy J Am Soc Nephrol 23 2012 123 130
132. M.S. Farvid, F. Homayouni, Z. Amiri, and F. Adelmanesh Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation Diabetes Res Clin Pract 93 2011 86 94
133. M.S. Farvid, M. Jalali, F. Siassi, and M. Hosseini Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes Diabetes Care 28 2005 2458 2464
134. S. Golbidi Antioxidants in the treatment of diabetes Curr Diabetes Rev 7 2011 106 125
135. S.S.M. Chung Contribution of polyol pathway to diabetes-induced oxidative stress J Am Soc Nephrol 14 2003 233 236
136. B.L. Mylari, S.J. Armento, D.A. Beebe, E.L. Conn, J.B. Coutcher, M.S. Dina, and et al. A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners J Med Chem 48 2005 6326 6339
137. J. Jedziniak, and J. Kinoshita Activators and inhibitors of lens aldose reductase Invest Ophthalmol Vis Sci 10 1971 357 366
138. E. Dvornik, N. Simard-Duquesne, M. Krami, K. Sestanj, K.H. Gabbay, J.H. Kinoshita, and et al. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor Science 182 1973 1146 1148
139. M.A. Ramirez, and N.L. Borja Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy Pharmacother: J Hum Pharmacol Drug Ther 28 2008 646 655
140. M. Chatzopoulou, P. Alexiou, E. Kotsampasakou, and V.J. Demopoulos Novel aldose reductase inhibitors: a patent survey (2006-present) Expert Opin Ther Pat 22 2012 1303 1323
141. M. Sedeek, G. Callera, A. Montezano, A. Gutsol, F. Heitz, C. Szyndralewiez, and et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy Am J Physiol Renal 299 2010 F1348 F1358
142. A.B. Sanz, M.D. Sanchez-Niño, A.M. Ramos, J.A. Moreno, B. Santamaria, M. Ruiz-Ortega, and et al. NF-kappaB in renal inflammation J Am Soc Nephrol 21 2010 1254 1262
143. P.E. Pergola, M. Krauth, J.W. Huff, D.A. Ferguson, S. Ruiz, C.J. Meyer, and et al. Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD Am J Nephrol 33 2011 469 476
144. M. Okamoto, M. Fuchigami, T. Suzuki, and N. Watanabe A novel CC chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models Biol Pharm Bull 35 2011 2069 2074
145. M. Petersen, M. Thorikay, M. Deckers, M. van Dinther, E.T. Grygielko, F. Gellibert, and et al. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis Kidney Int 73 2008 705 715 110
146. S.G. Adler, S. Schwartz, M.E. Williams, C. Arauz-Pacheco, W.K. Bolton, T. Lee, and et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria Clin J Am Soc Nephrol 5 2010 1420 1428
147. Z. Zhang, L. Sun, Y. Wang, G. Ning, A.W. Minto, J. Kong, and et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy Kidney Int 73 2008 163 171
148. Y. Li Podocytes as target of vitamin D Curr Diabetes Rev 7 2011 35 40
149. C. Morath, and M. Zeier Transplantation in type 1 diabetes Nephrol Dial Transplant 24 July (7) 2009 2026 2029
150. P. Robertson, C. Davis, J. Larsen, R. Stratta, D.E. Sutherland, and American Diabetes Association Pancreas transplantation in type 1 diabetes Diabetes Care 27 January (Suppl. 1) 2004 S105